Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination

Preventive Medicine

Volumn 48, Issue 5, 2009, Pages 432-437

  Howlett, Roberta I ^a   Miller, Anthony B ^b   Pasut, George ^a,b   Mai, Verna ^a,b  

^a Prevention and Screening   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cervical cancer prevention and control; Evaluation strategies; HPV vaccine; HPV related disease; Primary prevention; Secondary prevention

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAINSTORMING; CANADA; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH CARE PLANNING; HUMAN; IDENTIFICATION KEY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCHOOL CHILD; SCIENTIST; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; CANADA; CHILD; EARLY DIAGNOSIS; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 65549171227     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2008.12.022     Document Type: Article

References (61)

1. Anderson G.H., Benedet J.L., Le Riche J.C., Matisic J.P., and Thompson J.E. Invasive cancer of the cervix in British Columbia: a review of the demography and screening histories of 437 cases seen from 1985-1988. Obstet. Gynecol. 80 1 (1992) 1-4
2. Ault K.A. Long-term efficacy of human papillomavirus vaccination. Gynecol. Oncol. 107 Suppl 1 (2007) S27-S30 2
3. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 9576 (2007) 1861-1868
4. Ault K., and Reisinger K. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer. Int. J. Infect. Dis.: IJID: Off. Publ. Int. Soc. Infect. Dis. 11 Suppl 2 (2007) S26-S28
5. Benoit A.G., Krepart G.V., and Lotocki R.J. Results of prior cytologic screening in patients with a diagnosis of Stage I carcinoma of the cervix. Am. J. Obstet. Gynecol. 148 5 (1984) 690-694
6. Blackwell, T., 2008. Breakthrough Vaccine Victim of Bad Publicity.
7. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 4 (2002) 244-265
8. Bosch F.X., Castellsague X., and de Sanjose S. HPV and cervical cancer: screening or vaccination?. Br. J. Cancer 98 1 (2008) 15-21
9. Boyle P. IARC Projected World Cervical Cancer Burden (2004), EUROGIN
10. Brisson M., Van de Velde N., De Wals P., and Boily M.C. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ: Can. Med. Assoc. J. = Journal De l'Association Medicale Canadienne 177 5 (2007) 464-468
11. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 29 (2007) 5399-5408
12. Canadian Immunization Committee. Recommendations on a Human Papillomavirus Immunization Program, Minister of Health (2007), Health Canada, Ottawa, Ontario
13. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2008 (2008), Canadian Cancer Society, Toronto
14. Cancer Care Ontario. Ontario Cervical Screening Program: Program Report 2001-2005 (Selected Extracts) (2007), Cancer Care Ontario, Toronto, Ontario
15. Cancer Care Ontario, 2008. Cancer System Quality Index 2008: Cervical Cancer Screening. Available: http://www.cancercare.on.ca/english/csqi2008/csqiaccess/csqi-cerv-screen / [2008, 07/18].
16. Carmichael J.A., Jeffrey J.F., Steele H.D., and Ohlke I.D. The cytologic history of 245 patients developing invasive cervical carcinoma. Am. J. Obstet. Gynecol. 148 5 (1984) 685-690
17. Colgan T.J., Clarke A., Hakh N., and Seidenfeld A. Screening for cervical disease in mature women: strategies for improvement. Cancer 96 4 (2002) 195-203
18. Dempsey A.F., and Freed G.L. Human papillomavirus vaccination: expected impacts and unresolved issues. J. Pediatr. 152 3 (2008) 305-309
19. Dillner J., Arbyn M., and Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 148 2 (2007) 199-207
20. Elwood J.M., Cotton R.E., Johnson J., Jones G.M., Curnow J., and Beaver M.W. Are patients with abnormal cervical smears adequately managed?. Br. Med. J. (Clin. Res. ed.) 289 6449 (1984) 891-894
21. Erickson L.J., De Wals P., and Farand L. An analytical framework for immunization programs in Canada. Vaccine 23 19 (2005) 2470-2476
22. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26 Supplement 1 (2008) A16-A23
23. Franco E.L., Schlecht N.F., and Saslow D. The epidemiology of cervical cancer. Cancer J. (Sudbury, Mass.) 9 5 (2003) 348-359
24. Franco E.L., Bosch F.X., Cuzick J., et al. Chapter 29: knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 24 Suppl 3 (2006) S242-S249
25. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 Suppl 3 (2006) S171-177
26. Frisch M. On the etiology of anal squamous carcinoma. Dan. Med. Bull. 49 3 (2002) 194-209
27. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 19 (2007) 1915-1927
28. Gage J.C., Ferreccio C., Gonzales M., Arroyo R., Huivin M., and Robles S.C. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detec. Prev. 27 6 (2003) 466-471
29. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., and Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J. Natl. Cancer Inst. 100 5 (2008) 308-320
30. Harper D.M., Franco E.L., Wheeler C.M., et al., HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
31. Hartz L.E., and Fenaughty A.M. Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 1. Obstet. Gynecol. 98 4 (2001) 674-679
32. Health Canada, 2002. Cervical Cancer Screening in Canada: 1998 Surveillance Report. Her Majesty the Queen in Right of Canada, represented by the Minister of Public Works and Government Services Canada.
33. Herrero R. Chapter 7: human papillomavirus and cancer of the upper aerodigestive tract. J. Natl. Cancer Inst. Monographs 31 31 (2003) 47-51
34. Herrero R., Castellsague X., Pawlita M., et al., IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter Study. J. Natl. Cancer Inst. 95 23 (2003) 1772-1783
35. Hymel P.A. Decreasing risk: impact of HPV vaccination on outcomes. Am. J. Manag. Care 12 17 Suppl (2006) S473-S483
36. IARC. Working group on the evaluation of cancer-preventive strategies. IARC Handbooks of Cancer Prevention: Cervix Cancer Screening Vol. 10 (2005), IARC Press, Lyon, FR
37. Kim J.J., and Goldie S.J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359 8 (2008) 821-832
38. Kim J.J., Brisson M., Edmunds W.J., and Goldie S.J. Modeling cervical cancer prevention in developed countries. Vaccine 26S (2008) K76-K86 ICO Monograph
39. MacIsaac, M., 2008 05 21. Nova Scotia Cervical Screening Program.
40. Malchuk, C., 2006. Cervical cancer vaccine now available to girls and young women in Canada.
41. Marrett L.D., Innes M.K., Howlett R.I., and Cotterchio M. Cancer Care Ontario. Insight on Cancer, News and Information on Cervical Cancer (2005), Canadian Cancer Society (Ontario Division), Toronto
42. McKee M.D., Lurio J., Marantz P., Burton W., and Mulvihill M. Barriers to follow-up of abnormal Papanicolaou smears in an urban community health center. Arch. Fam. Med. 8 2 (1999) 129-134
43. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24S3 (2006) S1-S10
44. National Advisory Committee on Immunization, 2007. Canada Communicable Disease Report: Statement on Human Papillomavirus Vaccine.
45. Palm B.T., Kant A.C., Visser E.A., Vooijs G.P., van den Bosch W.J., and van Weel C. The effect of the family physician on improving follow-up after an abnormal PAP smear. Int. J. Qual. Health Care: J. Int. Soc. Qual. Health Care/ISQua 9 4 (1997) 277-282
46. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA: Cancer J. Clin. 55 2 (2005) 74-108
47. Paskett E.D., Phillips K.C., and Miller M.E. Improving compliance among women with abnormal Papanicolaou smears. Obstet. Gynecol. 86 3 (1995) 353-359
48. Peterson N.B., Han J., and Freund K.M. Inadequate follow-up for abnormal Pap smears in an urban population. J. Natl. Med. Assoc. 95 9 (2003) 825-832
49. Pfister H. Chapter 8: human papillomavirus and skin cancer. J. Natl. Cancer Inst. Monographs 31 31 (2003) 52-56
50. Picard, A., 2006. Vaccine against cervical cancer approved.
51. Provincial Cancer Prevention and Screening Council, 2006. Report on Cancer 2020: A Call for Renewed Action on Cancer Prevention and Detection in Ontario, Ontario.
52. Raffle A.E. Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ (Clin. Res. ed.) 335 7616 (2007) 375-377
53. Rubin M.A., Kleter B., Zhou M., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am. J. Pathol. 159 4 (2001) 1211-1218
54. Sarfati D., Cox B., Jones R.W., Sopoaga T., Rimene C., and Paul C. National audit of women with abnormal cervical smears in New Zealand. Aust. N. Z. J. Obstet. Gynaecol. 43 2 (2003) 152-156
55. Sasieni P.D., Cuzick J., and Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br. J. Cancer 73 8 (1996) 1001-1005
56. Saslow D., Castle P.E., Cox J.T., et al. American cancer society guideline for Human Papillomavirus (HPV) Vaccine use to prevent cervical cancer and its precursors. CA: Cancer J. Clin. 57 1 (2007) 7-28
57. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol. Oncol. 107 Suppl 1 (2007) S19-S23 2
58. Stanley M., and Villa L.L. Monitoring HPV vaccination. Vaccine 26 Supplement 1 (2008) A24-A27
59. Stuart G.C., McGregor S.E., Duggan M.A., and Nation J.G. Review of the screening history of Alberta women with invasive cervical cancer. CMAJ: Can. Med. Assoc. J. = Journal de l'Association Medicale Canadienne 157 5 (1997) 513-519
60. Villa L.L., Costa R.L., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95 11 (2006) 1459-1466
61. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 1 (1999) 12-19